address1,city,zip,country,phone,website,industry,industryKey,industryDisp,sector,sectorKey,sectorDisp,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,executiveTeam,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,trailingPE,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,tradeable,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,impliedSharesOutstanding,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,enterpriseToRevenue,enterpriseToEbitda,52WeekChange,SandP52WeekChange,quoteType,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,symbol,language,region,typeDisp,quoteSourceName,triggerable,customPriceAlertConfidence,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,regularMarketChangePercent,regularMarketPrice,corporateActions,regularMarketTime,exchange,messageBoardId,market,marketState,earningsCallTimestampStart,earningsCallTimestampEnd,isEarningsDateEstimate,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,sourceInterval,exchangeDataDelayedBy,averageAnalystRating,cryptoTradeable,shortName,longName,regularMarketChange,regularMarketDayRange,fullExchangeName,averageDailyVolume3Month,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekChangePercent,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,hasPrePostMarketData,firstTradeDateMilliseconds,trailingPegRatio
Gemenskapens gata 9,Mölndal,431 53,Sweden,46 3 17 88 21 50,https://www.xvivogroup.com,Medical Devices,medical-devices,Medical Devices,Healthcare,healthcare,Healthcare,"Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. The company was incorporated in 1998 and is headquartered in Mölndal, Sweden.",193,"[{'maxAge': 1, 'name': 'Mr. Christoffer  Rosenblad', 'age': 49, 'title': 'Chief Executive Officer', 'yearBorn': 1975, 'fiscalYear': 2024, 'totalPay': 7386000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kristoffer  Nordstrom', 'age': 39, 'title': 'Chief Financial Officer', 'yearBorn': 1985, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Lena  Hagman B.Sc.', 'age': 59, 'title': 'COO & Deputy CEO', 'yearBorn': 1965, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Ylva  Vihoj', 'age': 54, 'title': 'Senior Vice President of Human Resources', 'yearBorn': 1970, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Magnus  Nilsson Ph.D.', 'age': 68, 'title': 'Senior Advisor', 'yearBorn': 1956, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Andreas  Wallinder M.D., Ph.D.', 'age': 47, 'title': 'Chief Medical Officer', 'yearBorn': 1977, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Johan  Holmstrom', 'age': 54, 'title': 'Senior Vice President of Commercial Europe & RoW', 'yearBorn': 1970, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Jaya  Tiwari', 'age': 37, 'title': 'Senior Vice President of Clinical & Regulatory Affairs North America', 'yearBorn': 1987, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Mark  Reade', 'age': 61, 'title': 'Senior Vice President of North America', 'yearBorn': 1963, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}]",1735603200,[],86400,2,289.4,289.4,289.4,299.6,289.4,289.4,289.4,299.6,0.0,1.926,69.74359,50.62606,41777,41777,81847,61663,61663,298.6,299.8,0,0,9483922432,238.2,547.0,11.092553,302.76,396.626,0.0,0.0,SEK,False,8621487104,0.16024,24996719,31499500,0.09162,0.62279,31697600,66.427,4.504193,1735603200,1767139200,1743379200,136998000,4.29,5.91,10.084,71.71,-0.41902912,0.11844492,EQUITY,299.2,520.0,320.0,446.0,470.0,2.2,buy,6,315871008,10.028,120227000,29308000,3.585,5.202,854980992,1.401,27.143,0.02665,0.0669,641683008,-169347248,94448000,0.175,0.75052,0.14062001,0.12153,SEK,XVIVO.ST,en-US,US,Equity,Delayed Quote,True,HIGH,Europe/Stockholm,CEST,7200000,False,3.3863227,299.2,[],1752161370,STO,finmb_182486692,se_market,PREPRE,1752235200,1752235200,False,4.29,5.91,3.5125,85.181496,-3.5599976,-0.01175848,-97.425995,-0.24563693,15,0,2.2 - Buy,False,Xvivo Perfusion AB,Xvivo Perfusion AB (publ),9.800018,289.4 - 299.6,Stockholm,81847,61.000015,0.2560874,238.2 - 547.0,-247.79999,-0.45301643,-41.902912,1752211800,1752211800,1752211800,False,1349679600000,
